Gershoni-Baruch-Leibo Syndrome

Gershoni-Baruch-Leibo syndrome is an ultra-rare, inherited disorder in which a baby is born with a small area on the scalp where skin did not fully form (aplasia cutis congenita) and later shows very high near-sightedness (high myopia) together with a problem in the light-sensing cells of the retina called cone-rod dysfunction. “Cone-rod dysfunction” means both cone cells (used for color and sharp central vision) and rod cells (used for dim-light and side vision) do not work normally. Many reported children also have congenital nystagmus, which is rapid, involuntary eye movement from birth. The pattern was first described in a brother and sister from the same family, suggesting a genetic cause. Because so few patients have ever been reported, doctors consider this a very rare, oculocutaneous (eye-and-skin) syndrome. PubMed+2Genetic Diseases Center+2

Gershoni-Baruch–Leibo syndrome is a very rare genetic condition defined by the combination of (1) aplasia cutis congenita (ACC)—a patch of missing skin present at birth, commonly on the scalp; (2) pathologic high myopia (severe nearsightedness developing early); and (3) cone–rod dysfunction (a hereditary retinal disorder that first affects color and central vision and later can affect peripheral and night vision). Patients may also show congenital nystagmus (involuntary eye movements) and sometimes keratoconus (progressive corneal thinning). The disorder was first reported in two siblings by Ruth Gershoni-Baruch and R. Leibo in 1996; later summaries list Aplasia cutis–myopia syndrome and “aplasia cutis congenita, high myopia, and cone-rod dysfunction” as synonymous names. Monarch Initiative+3Wiley Online Library+3Genetic Diseases Center+3

How rare and how it runs in families. Medical databases list this syndrome as affecting far fewer than 1 in a million people. The original family report and several rare-disease catalogs describe autosomal recessive inheritance—a child is affected when both parents silently carry one changed copy of the same gene. Some summaries have repeated autosomal dominant by mistake; however, the original report and multiple catalog entries emphasize recessive inheritance, and no causative gene has been pinned down yet. PubMed+2Orpha+2

Other names

Doctors and databases use several names for the same pattern:

• Aplasia cutis-myopia syndrome (the most common catalog name).

• Aplasia cutis congenita, high myopia, and cone-rod dysfunction (descriptive name from the first medical paper).

• Gershoni-Baruch-Leibo syndrome (honors the two authors who first reported the sibling pair).

These names all point to the same triad: scalp skin defect + high myopia + cone-rod dysfunction, often with congenital nystagmus. PubMed+2Genetic Diseases Center+2

Types

There are no official subtypes because the total number of documented patients is extremely small. Clinicians may informally group cases by the dominant feature at presentation:

1. Cutaneous-dominant presentation: a newborn noted to have a small, hairless, scar-like area on the top midline of the scalp (aplasia cutis). Eye problems appear or are recognized later. NCBI

2. Ocular-dominant presentation: severe near-sightedness in early childhood, with nystagmus and vision problems leading to testing that reveals cone-rod dysfunction; a tiny healed scalp defect may be found only on careful exam. PMC+1

Because published series are so limited, “type” is mainly a practical way to think about first clues rather than a genetic subdivision. Monarch Initiative

---

Causes

For this syndrome, “cause” means genetic and developmental reasons that lead to the triad. A single precise gene has not been confirmed yet, but evidence points to inherited changes affecting how ectoderm (the early tissue that forms skin and eye structures) develops. Below are cause-level ideas and contributors doctors consider; each item explains what it means in plain language and points to supportive evidence from the original report and from established knowledge on its components (aplasia cutis congenita, high myopia, cone-rod disease, nystagmus):

1. Autosomal recessive inheritance — both parents are healthy carriers; the child gets two changed copies and shows the condition. PubMed+1

2. Ectodermal development error — early embryo tissue that forms skin and retina does not fully develop along the scalp midline and in retinal photoreceptors. NCBI

3. Pathways shared by skin and retina — many genes guide both hair/skin formation and photoreceptor health, so a single mutation can affect both systems. NCBI+1

4. Cone-rod dystrophy mechanisms — dozens of genes can disrupt cone and rod function; while this syndrome’s exact gene is unknown, the physiology matches cone-rod dysfunction biology. PMC+1

5. Early-onset high myopia mechanisms — some single-gene defects push the eye to grow too long, causing severe near-sightedness in childhood. PMC

6. Congenital nystagmus drivers — abnormal retinal or foveal development can trigger early nystagmus. AAO

7. Consanguinity (parents related) raises the chance two carriers share the same rare mutation, which aligns with the first family reported. PubMed

8. Unknown gene at an OMIM-listed locus — the condition is cataloged (OMIM 601075) but without a defined gene, reflecting rarity and limited families for mapping. MalaCards

9. Embryonic scalp midline closure problem — the top-of-scalp location suggests a focal closure or blood-supply issue in late first to early second trimester. NCBI

10. Photoreceptor metabolism stress — cones are energy-intense; many inherited defects first harm cones, then rods, matching a cone-rod pattern. The Lancet

11. Retinal pigment epithelium (RPE) involvement — some reports mention pigment changes, signaling RPE/photoreceptor crosstalk problems. Genetic Diseases Center

12. Extracellular matrix/scleral remodeling — abnormal signals can lengthen the eye, worsening high myopia. PMC

13. Variants overlapping with other oculocutaneous syndromes — conditions like Adams–Oliver or Knobloch can share features (scalp defects, severe myopia), reminding clinicians to confirm the exact triad. Wikipedia+1

14. Genetic heterogeneity — the same outward picture can result from different genes, which is common in rare eye-skin syndromes. PMC

15. Sporadic (new) mutation possibility — although the first family looked recessive, a new mutation in the egg or sperm can rarely produce a similar phenotype. Genetic Diseases Center

16. Limited gene panels — negative clinical genetic tests do not rule out a cause; the gene may not be on current panels. Eurofins Biomnis Connect

17. Copy-number variants (small deletions/duplications) can disrupt critical developmental genes even when DNA “spelling” is normal. (General rare-disease testing principle.) NCBI

18. Regulatory (non-coding) variants can mis-set gene “dimmer switches,” altering skin and retinal development. (General mechanism in inherited retinal disease.) PMC

19. Mitochondrial stress is unlikely primary — unlike classic mitochondrial syndromes, the hallmark here is the cone-rod plus scalp defect triad. (Included to clarify differences.) Cleveland Clinic

20. Gene unknown today — the best current statement is: “ultra-rare recessive oculocutaneous syndrome; causative gene not yet identified.” MalaCards+1

---

Symptoms and signs

1. Aplasia cutis congenita of the midline scalp: a small area at the top of the head where skin was absent at birth; it often heals with a hairless, thin scar. PubMed+1

2. High myopia (severe near-sightedness): very strong negative eyeglass power from early childhood; the eye is longer than normal, making distant objects blurry. PMC

3. Congenital nystagmus: eyes make quick, repetitive movements from infancy, which can blur vision. PubMed

4. Cone-rod dysfunction: trouble with color and fine detail first (cones), later also difficulty in dim light and side vision (rods). Electroretinogram confirms this pattern. PubMed+1

5. Reduced visual acuity: even with glasses, sharpness can be below average because the retina’s sensors are not working normally. PMC

6. Photophobia (light sensitivity): bright light can be uncomfortable due to cone dysfunction. PMC

7. Color vision problems: colors may look washed out or hard to distinguish. PMC

8. Night vision difficulty: as rods become involved, navigating in dim light gets harder. PMC

9. Abnormal retinal pigmentation on exam: the eye doctor may see patchy changes at the back of the eye. Genetic Diseases Center

10. Keratoconus risk (in some summaries): the cornea may thin and steepen, which can add irregular astigmatism. (Listed as an associated finding in summaries.) Wikipedia

11. Easily scarred scalp skin over the lesion: the aplasia area can remain delicate and scar-prone. Genetic Diseases Center

12. Head shape normal except for small calvarial defect beneath the skin patch (sometimes): bone under the lesion can be thin. Genetic Diseases Center

13. Normal general growth and intelligence in limited reports: the core issues are skin and eyes; systemic problems are not a required feature. (Based on sparse case descriptions.) PubMed

14. Family history compatible with recessive pattern: affected siblings with healthy parents may be seen in carrier families. PubMed

15. Symptom onset: scalp finding is present at birth; the eye findings become clear in infancy/early childhood. Genetic Diseases Center

---

Diagnostic tests

A) Physical examination

1. Newborn scalp inspection: look for a small, well-demarcated, hairless patch at the midline vertex that looks scar-like; measure size and check for tenderness or open areas. NCBI

2. Whole-body skin check: rule out multiple lesions or patterns that might suggest a different syndrome (e.g., Adams–Oliver). Wikipedia

3. Head palpation: feel the skull under the lesion to assess for subtle bony thinning. Genetic Diseases Center

4. General pediatric exam: ensure growth, tone, and organ systems are otherwise typical; this helps with differential diagnosis. Genetic Diseases Center

5. Family examination: check parents and siblings for tiny midline scars or high myopia that could hint at carrier/related traits. Genetic Diseases Center

B) Manual / bedside eye tests

6. Refraction (retinoscopy or automated): measures eyeglass power; confirms high myopia. PMC

7. Best-corrected visual acuity (age-appropriate charts): establishes baseline sharpness. PMC

8. Color vision testing: detects cone-mediated color loss (e.g., Ishihara, pediatric alternatives). PMC

9. Contrast sensitivity: picks up subtle cone dysfunction not seen on acuity alone. PMC

10. Amsler grid or central field checks (when old enough): screens for central distortion from cone disease. PMC

C) Laboratory / pathology / genetics

11. Genetic counseling + inheritance review: documents family structure and explains recessive risk (25% for each pregnancy when both parents are carriers). Genetic Diseases Center

12. Targeted retinal dystrophy gene panel or exome sequencing: even if the exact gene is unknown, testing can rule in/out known cone-rod genes and reveal candidates. PMC+1

13. Copy-number variant analysis (CMA/MLPA): looks for small deletions/duplications. NCBI

14. Skin biopsy (only if the lesion is atypical or non-healing): most scalp defects are diagnosed clinically; biopsy is reserved for unusual cases. NCBI

15. Routine labs are usually not diagnostic for this genetic syndrome; they are used only to manage complications (e.g., infection of the scalp area). PMC

D) Electrodiagnostic tests

16. Full-field electroretinography (ERG): measures electrical responses from cones and rods; shows reduced cone signals and later rod involvement—typical of cone-rod dysfunction. PMC

17. Multifocal ERG (when feasible): maps cone function across the macula to quantify central dysfunction. PMC

18. Visual evoked potentials (VEP): checks the pathway from retina to brain; helps when acuity cannot be measured well due to nystagmus. AAO

E) Imaging tests

19. Scalp ultrasound or low-dose CT (rarely needed): if the lesion is large or atypical, imaging can check the underlying skull. NCBI

20. Dermoscopy of the scalp scar: noninvasive magnified view to document features and healing. NCBI

Eye imaging suite:

• Dilated fundus photography: documents pigment changes and optic nerve/macula appearance over time. Genetic Diseases Center

• Optical coherence tomography (OCT): shows the layers of the retina and fovea; may reveal thinning or structural changes that match cone problems. The Lancet

• Axial length biometry: measures eye length; very long eyes support high-myopia diagnosis. PMC

• Keratometry/corneal topography: checks for keratoconus if vision fluctuates or astigmatism is irregular. Wikipedia

• Perimetry (visual fields): tests side vision to track rod involvement over time. PMC

Non-pharmacological treatments

1. Moist wound healing for small ACC lesions.
   Description (≈150 words). Keeping the scalp lesion clean, moist, and protected helps the skin re-epithelialize. Clinicians use non-adherent dressings, gentle cleansing, and topical antimicrobials (when indicated). Parents are taught hand hygiene, dressing changes, and signs of infection (redness, warmth, discharge, fever). Most small ACC lesions heal over weeks and leave a thin scar or hairless patch. Purpose. Promote safe closure without surgery. Mechanism. A moist environment optimizes keratinocyte migration and reduces crusting, allowing continuous epithelial repair while lowering infection risk. PMC+1

2. Protective head gear / padding in infancy.
   Description. Soft caps or padded headbands help protect a healing scalp area from trauma. Purpose. Prevent bleeding/infection from accidental bumps while the lesion matures. Mechanism. Physical barrier distributes minor impacts and reduces friction over fragile tissue. PMC

3. Early low-vision assessment.
   Description. A pediatric low-vision team evaluates visual acuity, contrast, fields, and functional needs (reading distance, lighting, classroom positioning). Purpose. Maximize functional sight and learning from infancy onward. Mechanism. Tailored optical and environmental strategies compensate for cone dysfunction and myopia. Retina Today

4. High-contrast, magnification, and task lighting.
   Description. Use high-contrast materials, bold fonts, electronic magnifiers (CCTV/tablets), and bright, glare-controlled lighting. Purpose. Improve reading speed and accuracy despite reduced central acuity and contrast. Mechanism. Increases retinal image size and signal-to-noise for impaired cones. Retina Today

5. Tinted/filtered lenses and wide-brim hats.
   Description. Tints (e.g., gray, amber) and brimmed hats reduce photophobia and glare outdoors. Purpose. Comfort and better function in bright light. Mechanism. Reduces incident light and short-wavelength scatter on already light-sensitive retinas. Retina Today

6. Orientation & mobility training.
   Description. Specialists teach safe movement, navigation, and use of residual vision. Purpose. Independence and safety, especially if peripheral vision declines. Mechanism. Behavioral training substitutes for reduced visual cues. Retina Today

7. Educational accommodations (IEP/504-style).
   Description. Preferential seating, enlarged print, extra time, and digital resources. Purpose. Equal access to learning. Mechanism. Removes visual barriers and fatigue. Retina Today

8. Keratoconus stabilization with corneal cross-linking (CXL) when indicated.
   Description. If keratoconus is confirmed/progressive, ophthalmologists may recommend CXL to halt biomechanical weakening. Purpose. Preserve corneal shape and prevent worsening of irregular astigmatism. Mechanism. Riboflavin + UV-A induce collagen cross-links, stiffening corneal stroma. PMC+1

9. Scleral or rigid gas-permeable lenses for irregular astigmatism.
   Description. Specialty contact lenses vault corneal irregularities and provide a smooth optical surface. Purpose. Improve best-corrected vision where glasses are insufficient. Mechanism. Tears + lens act as a new, regular refracting surface. PMC

10. Periodic retinal surveillance in high myopia.
    Description. Dilated fundus exams and patient education (“flashes/floaters/curtain” urgent signs). Purpose. Early detection of retinal tears/detachments. Mechanism. Proactive monitoring reduces risk of vision-threatening complications. Retina Today

11. Nystagmus visual function optimization (head posture coaching).
    Description. Identify the “null point” and allow ergonomic seating to match head turn; prism glasses may be considered. Purpose. Better acuity and comfort. Mechanism. Aligns gaze where nystagmus amplitude is least. Lippincott Journals

12. Nystagmus surgery (Kestenbaum–Anderson) when severe head turn).
    Description. Eye muscle surgery repositions the null point toward straight ahead. Purpose. Reduce abnormal head posture, sometimes improving function. Mechanism. Recession/resection of extraocular muscles shifts ocular motor equilibrium. AAO Journal+2PMC+2

13. ACC surgical reconstruction for large/complex defects.
    Description. For big lesions or exposed bone/dura: options include flaps, grafts, dermal matrices, and staged repairs with tissue expanders. Purpose. Protect intracranial structures, prevent infection, and achieve durable coverage. Mechanism. Restores skin barrier and structural integrity. Medscape+1

14. Ultra-high-frequency ultrasound to guide ACC debridement.
    Description. Specialized ultrasound can map superficial brain/dura under large scalp defects to guide safe surgical steps. Purpose. Reduce bleeding/neurologic complications. Mechanism. High-resolution imaging (≈30 µm) delineates critical anatomy before debridement. Lippincott Journals

15. Infection prevention bundle (ACC).
    Description. Hand hygiene, clean dressings, early recognition of cellulitis, and timely antibiotics if indicated. Purpose. Prevent local/systemic infection during healing. Mechanism. Reduces bacterial load and barrier compromise. PMC

16. Family genetic counseling.
    Description. Review inheritance uncertainties (AR vs AD described), recurrence risks, and options for genomic evaluation as technology evolves. Purpose. Informed decisions and surveillance for siblings. Mechanism. Risk assessment based on limited but growing literature. Genetic Diseases Center

17. Clinical-trial referral for inherited retinal diseases.
    Description. Screen eligibility for cone/cone–rod/rod–cone dystrophy trials (gene-agnostic or gene-specific). Purpose. Access to emerging treatments and structured follow-up. Mechanism. Investigational vectors, neuroprotection, or optogenetics (trial stage dependent). ClinicalTrials.gov+1

18. Digital accessibility and assistive tech.
    Description. Text-to-speech, large-print OS settings, and screen magnifiers. Purpose. Daily function and academic/work success. Mechanism. Software-based magnification/contrast enhancement. Retina Today

19. UV protection & lifestyle eye safety.
    Description. Sunglasses with UV-A/UV-B blocking and avoiding ocular trauma. Purpose. Comfort and risk reduction. Mechanism. Limits phototoxic stress and injury risk. Retina Today

20. Psychosocial support.
    Description. Counseling and family support networks for chronic visual impairment. Purpose. Quality of life and adherence. Mechanism. Coping strategies reduce stress and improve participation. Retina Today

---

Drug treatments

Important note: There is no disease-specific curative drug for Gershoni-Baruch–Leibo syndrome. Medicines are used symptomatically for ACC wound care, high myopia control, ocular surface comfort, and nystagmus—drawing on broader evidence for these problems. Always individualize dosing with the treating clinician, especially in infants/children.

1. Topical antibiotic ointment for small ACC (e.g., mupirocin 2% 1–3×/day short course).
   Class. Topical antibacterial. Purpose. Lower local infection risk while re-epithelializing. Mechanism. Inhibits bacterial protein synthesis. Side effects. Local irritation, rare allergy. PMC

2. Non-adherent antimicrobial dressings (e.g., silver-impregnated gauze per local protocols).
   Class. Topical antimicrobial dressing. Purpose. Maintain moist, clean environment. Mechanism. Silver ions disrupt bacterial membranes. Side effects. Skin staining/irritation; use with pediatric guidance. PMC

3. Oral antibiotics (when ACC shows infection—agent per culture/age).
   Class. Systemic antibacterial. Purpose. Treat cellulitis or systemic signs. Mechanism. Pathogen-specific. Side effects. GI upset, allergy; antibiotic stewardship required. PMC

4. Analgesia for dressing changes (e.g., infant-appropriate acetaminophen per weight).
   Class. Analgesic/antipyretic. Purpose. Comfort. Mechanism. Central COX inhibition. Side effects. Dosing errors can cause hepatotoxicity—medical supervision essential. PMC

5. Low-dose atropine eye drops for myopia progression (e.g., 0.01% nightly; pediatric ophthalmology dosing).
   Class. Muscarinic antagonist. Purpose. Slow myopia progression in children. Mechanism. Modulates scleral/choroidal signaling to reduce axial growth. Side effects. Mild photophobia or near blur at higher concentrations. PMC+2PMC+2

6. Lubricating eye drops/gel (carboxymethylcellulose, HA) PRN.
   Class. Ocular lubricants. Purpose. Ocular surface comfort, reduce glare/irritation. Mechanism. Tear film stabilization. Side effects. Transient blur. Wiley Online Library

7. Gabapentin for congenital/infantile nystagmus (e.g., adult studies used 1200 mg/day; pediatric dosing specialist-guided).
   Class. GABA analogue. Purpose. Reduce nystagmus intensity, improve foveation in selected patients. Mechanism. Modulates neuronal excitability. Side effects. Drowsiness, dizziness. PubMed+1

8. Memantine for nystagmus (e.g., adult trials used up to 40 mg/day; pediatric specialist oversight).
   Class. NMDA receptor antagonist. Purpose. Similar to gabapentin; may improve acuity and reduce oscillations. Mechanism. Glutamatergic modulation. Side effects. Headache, dizziness. PubMed

9. Topical antibiotics post-CXL or contact lens fitting (per protocol).
   Class. Ophthalmic antibacterial. Purpose. Infection prophylaxis after procedures. Mechanism. Reduces microbial load. Side effects. Local irritation. ascrs.org

10. Topical corticosteroids post-CXL (short course, protocolized).
    Class. Anti-inflammatory. Purpose. Control post-procedure inflammation. Mechanism. Inhibits inflammatory signaling. Side effects. Steroid response IOP rise—requires monitoring. ascrs.org

11. Antihistamine/mast-cell stabilizer drops for photophobia-linked irritation (PRN).
    Class. Dual-action anti-allergy drops. Purpose. Reduce surface itch/tearing that worsens visual comfort. Mechanism. H1 blockade + mast-cell stabilization. Side effects. Bitter taste, transient sting. (General ocular surface management references.) Wiley Online Library

12. Cycloplegic refraction agents (atropine/cyclopentolate) used diagnostically.
    Class. Antimuscarinics. Purpose. Accurate refraction in high myopia. Mechanism. Temporarily relax accommodation. Side effects. Photophobia/blur; used under supervision. PMC

13. Antimicrobial dressings with acellular dermal matrices (peri-op protocols).
    Class. Device + antimicrobial adjunct. Purpose. Support grafts/flaps in large ACC. Mechanism. Scaffold for tissue regeneration and infection control. Side effects. Graft failure risk. BioMed Central

14. Analgesia/antiemetics peri-op for ACC reconstruction.
    Class. Multimodal analgesia. Purpose. Comfort and safety. Mechanism. Standard peri-op care. Side effects. Depends on agent; anesthesiology-guided. Frontiers

15. Topical riboflavin during CXL (procedure drug).
    Class. Photosensitizer. Purpose. Enable UV-A cross-linking. Mechanism. Generates reactive species to create collagen bonds. Side effects. Corneal haze transiently. ascrs.org

16. Antibiotic prophylaxis for infected ACC per culture (e.g., cephalexin if MSSA suspected—clinician-directed).
    Class. Systemic antibiotic. Purpose. Treat infection threatening healing. Mechanism. Cell-wall or protein synthesis inhibition. Side effects. Allergy, GI upset. PMC

17. Pain-relief eye drops post-procedure (short term, preservative-free).
    Class. Topical NSAID/anaesthetic (used cautiously). Purpose. Comfort after CXL/PRK-like epi removal. Mechanism. COX inhibition/nerve blockade. Side effects. Delayed healing with overuse—ophthalmologist-guided. ascrs.org

18. Antibiotic ointment for contact lens-related abrasions (as indicated).
    Class. Ophthalmic antibiotic. Purpose. Prevent microbial keratitis. Mechanism. As above. Side effects. Local irritation. PMC

19. Artificial tears gel/ointment at night.
    Class. Lubricant. Purpose. Nighttime comfort for exposure/oscillation-related dryness. Mechanism. Longer ocular surface retention. Side effects. Morning blur. Wiley Online Library

20. Vitamin A–containing formulations—not standard for cone–rod dystrophy and can be harmful in excess—generally not recommended unless a specialist prescribes for a specific indication.
    Class. Fat-soluble vitamin. Purpose/mechanism. Historically explored in other retinal diseases, but not standard in COD/CORD; hypervitaminosis risk. Side effects. Hepatotoxicity, teratogenicity. (General caution drawn from retinal nutrition literature.) PMC

---

Dietary molecular supplements

Caution: Supplements are adjunctive for comfort or general ocular health; none are proven to cure cone–rod dystrophy. Discuss safety (especially in children/pregnancy) with clinicians.

1. Lutein (10–20 mg/day) + Zeaxanthin (2–10 mg/day).
   Description (≈150 words). These macular carotenoids concentrate in the fovea and filter blue light. In AMD and healthy adults, supplementation increases macular pigment and may improve some visual performance measures; for inherited dystrophies, evidence is extrapolated, not definitive. Function. Photoprotection and antioxidant support. Mechanism. Quenching reactive oxygen species and filtering short-wavelength light at the photoreceptor level. Evidence highlights. Randomized and observational studies in AMD show improved macular pigment and visual functions; mechanistic plausibility extends to other retinal stress states. PMC+2IOVS+2

2. Omega-3 fatty acids (EPA/DHA 1–2 g/day in adults; pediatric dosing clinician-guided).
   Description. Omega-3s can improve symptoms in dry eye disease, which may relieve ocular surface discomfort in highly myopic or low-vision patients; RCTs show mixed results but meta-analyses often find benefit. Function. Anti-inflammatory tear stabilization. Mechanism. Membrane incorporation, resolvin pathways. Wiley Online Library+2PubMed+2

3. Coenzyme Q10 (ubiquinone/ubiquinol; common oral doses 100–200 mg/day in adults).
   Description. Mitochondrial electron-transport cofactor with antioxidant effects; preclinical and small clinical literature suggests neuroprotection in retinal stress models. Function. Support mitochondrial health. Mechanism. Scavenges ROS, stabilizes mitochondrial membranes. PMC+2IOVS+2

4. Balanced multivitamin without excess vitamin A (age-appropriate).
   Description. General micronutrient adequacy supports wound healing and ocular surface health; avoids hypervitaminosis A risks. Function. Nutritional baseline. Mechanism. Cofactor provision for cellular repair. PMC

5. Antioxidant-rich diet pattern (Mediterranean-style).
   Description. Emphasizes fruits/vegetables, leafy greens, fish, olive oil, nuts; used in many ocular health recommendations. Function. Systemic anti-inflammatory milieu. Mechanism. Dietary polyphenols and carotenoids reduce oxidative stress. PMC

6. Hydration + humidified environment.
   Description. Simple measures that help ocular surface comfort with lubricants. Function. Tear film stability. Mechanism. Reduces evaporative loss. Wiley Online Library

7. Zinc (within RDA; avoid high-dose in children).
   Description. Zinc is a cofactor in retinal metabolism; very high chronic doses can cause harm—use only within dietary guidelines. Function. Enzymatic support. Mechanism. Cofactor for antioxidant enzymes. PMC

8. Vitamin C/E (dietary intake within RDA).
   Description. Antioxidants with ocular relevance; supplementation beyond diet hasn’t been proven for COD/CORD but adequate intake is reasonable. Function. ROS scavenging. Mechanism. Non-enzymatic antioxidant defense. PMC

9. Macular-health formulations (AREDS2-style) for adults if comorbid AMD—not for COD/CORD alone.
   Description. AREDS2 (lutein/zeaxanthin + antioxidants + zinc) slows AMD progression, not inherited dystrophies; consider only if AMD is present. Function. Disease-specific for AMD. Mechanism. As above. PMC

10. Dietary counseling to maintain healthy weight and omega-3-rich intake.
    Description. Practical planning to sustain long-term ocular surface and vascular health. Function. Support general wellbeing that aids coping with visual impairment. Mechanism. Systemic anti-inflammatory and metabolic benefits. Wiley Online Library

---

Immunity-booster / regenerative / stem-cell” drugs

Critical safety note: No immune-booster or stem-cell drug is proven to cure this syndrome. Items below reflect research directions in inherited retinal diseases; participation occurs only within regulated clinical trials.

1. Gene therapy vectors for cone/rod dystrophies (trial-specific).
   Dose. Surgical subretinal or intravitreal (per protocol). Function/mechanism. Deliver functional gene or modifier to photoreceptors/retinal cells to slow degeneration. ClinicalTrials.gov+1

2. Neuroprotective small molecules (e.g., investigational agents targeting oxidative stress).
   Dose. Trial-based. Function/mechanism. Reduce retinal cell apoptosis by modulating oxidative/mitochondrial pathways. PMC

3. Optogenetic therapies (experimental).
   Dose. Vector-delivered opsins to inner retinal cells. Function/mechanism. Re-sensitize non-photoreceptor cells to light. Nature

4. Cell-based retinal progenitor therapies (early-phase studies).
   Dose. Subretinal/intravitreal per protocol. Function/mechanism. Provide trophic support or replace damaged cells; still investigational. Nature

5. Topical mitochondrial support (experimental CoQ10 formulations).
   Dose. Trial-defined. Function/mechanism. Enhance retinal mitochondrial resilience; promising preclinical data. Frontiers

6. Anti-fibrotic/ECM modulators for keratoconus (adjunct to CXL; research space).
   Dose. Protocol-specific. Function/mechanism. Aim to optimize corneal remodeling and healing. PMC

---

Surgeries

1. Corneal cross-linking (CXL).
   Procedure. Epithelial removal (or transepithelial), riboflavin instillation, UV-A exposure. Why. To stop keratoconus from getting worse and preserve quality of vision. PMC+1

2. Kestenbaum–Anderson nystagmus surgery.
   Procedure. Recession/resection pattern on horizontal recti to shift the null point. Why. Reduce abnormal head posture and sometimes improve functional vision. AAO Journal+1

3. ACC scalp reconstruction (flaps/grafts/dermal matrices).
   Procedure. Local or regional flaps, split-thickness skin grafts, and/or acellular dermal matrix; staged approaches with tissue expanders as needed. Why. Protect brain/skull, prevent infection, and close large defects. Medscape+1

4. Debridement guided by ultra-high-frequency ultrasound (for complex ACC).
   Procedure. High-resolution mapping of dura/sinus followed by careful debridement and closure. Why. Reduce catastrophic bleeding and neurologic injury. Lippincott Journals

5. Corneal transplantation (rare, advanced keratoconus).
   Procedure. Deep anterior lamellar or penetrating keratoplasty when scarring or ectasia is severe despite CXL and specialty lenses. Why. Restore corneal clarity/regularity when other treatments fail. PMC

---

Preventions

1. Prompt ACC wound care education to caregivers. PMC

2. Infection-prevention hygiene around healing scalp lesions. PMC

3. Early diagnosis of keratoconus (topography) in teens with high myopia; treat progression early with CXL. PMC

4. Regular dilated exams for high-myopia retinal risks; urgent evaluation for flashes/floaters/curtain. Retina Today

5. UV protection outdoors to reduce photophobia and potential phototoxic stress. Retina Today

6. Consistent spectacle/contact-lens wear to optimize acuity and reduce eye strain. Retina Today

7. Avoid eye rubbing (keratoconus risk). PMC

8. Healthy diet with leafy greens and fish (adjunctive ocular health). PMC

9. School accommodations to prevent academic delays from low vision. Retina Today

10. Discuss family planning/genetic counseling given reported familial cases. Genetic Diseases Center

---

When to see doctors

• Immediately (emergency/urgent): Any ACC lesion that bleeds, smells foul, rapidly enlarges, or is near open bone/dura; any eye symptom of sudden flashes, new floaters, or a curtain/shadow—possible retinal tear/detachment. PMC+1

• Soon (days–weeks): Increasing head turn from nystagmus, quick myopia progression, or signs of keratoconus (worsening irregular blur/ghosting). PMC

• Routine: Regular pediatric, dermatology/plastic surgery (if ACC was large), and ophthalmology follow-ups (refractive updates, retinal checks, corneal imaging, low-vision care). PMC+1

---

What to eat and what to avoid

1. Do eat: Dark leafy greens, orange/yellow vegetables, and other carotenoid-rich foods (spinach, kale, corn). Why: Provide lutein/zeaxanthin supportive of macular health. PMC

2. Do eat: Fatty fish (e.g., salmon, sardines) weekly for omega-3s; discuss supplements if diet is low. Wiley Online Library

3. Do stay hydrated and consider room humidification to ease ocular surface symptoms. Wiley Online Library

4. Do maintain balanced meals supporting growth and wound healing (adequate protein, vitamins, zinc within RDA). PMC

5. Avoid excessive vitamin A supplements unless specifically prescribed. PMC

6. Avoid smoke exposure (ocular surface irritant and general health risk). (General ocular surface care principles.) Wiley Online Library

7. Limit ultra-processed, high-sugar foods that worsen systemic inflammation. (Dietary pattern evidence for ocular health.) PMC

8. Choose sunglasses and hats outdoors as part of “diet” for light exposure—think of light as an environmental “intake.” Retina Today

9. Use age-appropriate multivitamin only if dietary gaps exist, not mega-doses. PMC

10. Coordinate any supplement use with your clinicians, especially for children, pregnancy, or when on other medicines. (Safety principle.) Wiley Online Library

---

FAQs

1) Is Gershoni-Baruch–Leibo syndrome the same as Aplasia cutis–myopia syndrome?
Yes. The terms are used as synonyms in rare-disease databases describing the triad of ACC, high myopia, and cone–rod dysfunction. Genetic Diseases Center+1

2) How many cases exist?
Only a handful of families/cases are published, starting with the 1996 sibling report; the entity remains ultra-rare. Wiley Online Library

3) What is the inheritance?
Sparse literature mentions autosomal recessive and, in some catalog notes, possible autosomal dominant transmission; a single gene hasn’t been firmly established. Genetic Diseases Center

4) Is there a cure?
No disease-specific cure exists; management targets the components (ACC, myopia, cone–rod dysfunction, nystagmus, keratoconus). NCBI+1

5) Can low-dose atropine help the high myopia?
Yes—multiple trials and reviews show low-dose atropine (e.g., 0.01%) slows progression in children; dosing is specialist-guided. PMC+1

6) Will glasses fix cone–rod dysfunction?
Glasses correct refractive error but can’t reverse photoreceptor disease; low-vision aids and accessibility strategies are crucial. Retina Today

7) Are there gene therapies?
There are active clinical trials for related cone/rod dystrophies; none specific to this eponym yet. Consider trial screening at qualified centers. ClinicalTrials.gov+1

8) What about keratoconus?
If present and progressive, corneal cross-linking can halt progression; specialty lenses often improve vision. PMC

9) Can medicines reduce nystagmus?
Some adults benefit from gabapentin or memantine; pediatric use requires specialist oversight. Surgery can help abnormal head posture. PubMed+1

10) Do ACC scalp lesions always need surgery?
No. Many small lesions heal conservatively with dressings; large/complex defects may need surgical reconstruction. PMC+1

11) What complications should families watch for?
For ACC: infection, bleeding; for eyes: symptoms of retinal tear/detachment, worsening irregular vision (possible keratoconus), or increasing head turn. PMC+1

12) What tests confirm the eye diagnosis?
Full pediatric ophthalmology examination, electroretinography (ERG), optical coherence tomography (OCT), visual fields, color testing, and corneal topography for keratoconus when appropriate. (Standard COD/CORD and keratoconus work-ups.) Nature+1

13) Are dietary supplements necessary?
They’re not curative; some (lutein/zeaxanthin, omega-3s) may support ocular comfort/health. Avoid excess vitamin A unless specifically prescribed. PMC+1

14) Can children attend mainstream schools?
Yes—with early low-vision services and accommodations, most children can learn effectively. Retina Today

15) Where can I read the original medical descriptions?
See the 1996 first report by Gershoni-Baruch & Leibo (American Journal of Medical Genetics) and rare-disease summaries (GARD/Orphanet/Monarch). Monarch Initiative+3Wiley Online Library+3Genetic Diseases Center+3

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 20, 2025.